ImageneBio (IMA) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImageneBio (IMA) has outperformed Tevogen (TVGN) over the past year, losing 44.7% versus a loss of 82.5%. ImageneBio is the larger company by market cap ($46.9 million vs $39.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMA | TVGN |
|---|---|---|
| Share price | $4.12 | $6.00 |
| Market cap | $46.86M | $39.07M |
| 1-day change | -10.63% | -7.55% |
| YTD return | -33.19% | -60.79% |
| 1-year return | -44.72% | -82.51% |
| 5-year return | -96.83% | — |
| EPS (TTM) | $-4.09 | $-6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.10 | $39.00 |
| 52-week low | $3.94 | $3.64 |
| Distance from 52-week high | -54.73% | -84.62% |
| Average volume | 12.81K | 9.75K |
| Shares outstanding | 11.37M | 6.51M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMA has outperformed TVGN by 37.8 percentage points over the past year.
IMA vs TVGN FAQ
Which is bigger, ImageneBio or Tevogen?
ImageneBio (IMA) is larger, with a market capitalization of $46.86M compared with $39.07M for Tevogen (TVGN).
Which stock has performed better over the past year, IMA or TVGN?
IMA returned -44.72% over the past 12 months, compared with -82.51% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are ImageneBio and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.